Clinical Trial

Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
this is an investigator-initiated trial aimed at evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Patients With B cell mediated autoimmune disease.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-23; most recent amendment 2025-11-24.
Status change: Not Yet Recruiting → Recruiting 2025-02-09
Trial Details
NCT Number NCT06792799
Lead Sponsor The Children's Hospital of Zhejiang University School of Medicine
Conditions Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome, IgAN - IgA Nephropathy
Enrollment 36 participants
Start Date 2025-01-30
Primary Completion 2028-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-01